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SUMMARY
The thesis examines sequential mining approaches in the context of treatment rec-
ommendation for Gliblastoma (GBM) patients. GBM is the most lethal and biologically
the most aggressive forms of brain tumor with median survival of approximately 1 year.
A significant challenge in treating such rare forms of cancer is to make the best decision
about optimal treatment plans for patients after standard of care. We tailor the existing
sequential mining approaches by adding constraints to mine significant treatment options
for cancer patients. The goal of the work is to analyze which treatment patterns play a
role in prolonging the survival period of patients. In addition to the treatment analysis, we
also discover some interesting clinical and genomic factors, which influence the survival
period of patients.
A treatment advisor tool has been developed based on the predictive features discovered.
This tool is used to recommend treatment guidelines for a new patient based on the treat-
ments meted out to other patients sharing clinical similarity with the new patient. The
recommendations are also guided by the influential treatment patterns discovered in the
study. The tool is based on the notion of patient similarity and uses a weighted function
to calculate the same.
The recommendations made by the tool may influence the clinicians to have the patients
record some vital data on their own. With the progression of the treatment the clinicians
may want to add to or modify some of the vital data elements previously decided to be
recorded. In such a case a static database would not be very efficient to record the data
since manual intervention is inevitable to incorporate the changes in the database struc-
ture. To solve this problem we have developed a dynamic database evolution framework,
which uses a form based interface to interact with the clinician to add or modify the data
ix
elements in a database. The clinicians are flexible to create a new form for patients or
modify existing forms based on a patient’s condition. As a result, appropriate schema
modifications would be done in the relational database at the backend to incorporate




1.1 Importance of Cancer Study
Cancers have become of the leading causes of morbidity and mortality worldwide
in the recent past with 14 million new cases reported along with 8.2 million cancer
related deaths in 2012 [46]. Early diagnosis of cancer can lead to formulation of
effective treatment plans since every cancer type has a different treatment regimen
and multiple modalities such as surgery, radiotherapy, chemotherapy, etc. A patient’s
quality of life is an important goal when deciding on treatments but the primary goal
is to cure cancer and prolong the survival period. [47].
1.1.1 Glioblastoma
Glioblastoma (GBM) is the most lethal and biologically the most aggressive brain can-
cer with patients having a median survival of 12-15 months. [45]. A small percentage
of patients survive for longer period of times. Understanding what factors prolong
survival and promote treatment responses can be of value to treating physicians.The
Cancer Genome Atlas (TCGA) [27], a project of the National Institutes of Health
(NIH), led to work done on classifying Glioblastoma into four distinct molecular sub-
types which may lead to different treatment regimens [12]. Patients with certain
molecular subtypes may have greater overall survival than other patient subtypes
and analyzing gene expression levels, copy number variation (CNV), and mutations
may give us information about their correlation with survival periods. The current
standard of care for new GBM patients involves surgical resection followed by radia-
tion therapy and chemotherapy with the oral alkylating agent Temodar [33].Krex et
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al [20] have analyzed newly diagnosed GBM patients undergoing therapy and discov-
ered certain clinical and molecular features which play a significant role in prolonging
the survival period. Predictive survival models have been developed in the past utiliz-
ing imaging and clinical features of patients [24] but few have comprehensively studied
the impact of treatments in addition to clinical features and genomic features. The
high mortality rate of GBM patients, where long-term survival is a rare phenomenon,
has drawn significant attention to improving treatment of these tumors. After first
line standard of care treatment, there are different treatment combinations chosen
by oncologists. The sequence in which the next set of drugs or therapy is prescribed
adds to the level of complexity since drugs given in a particular sequence may have
a better therapeutic effect than the same drugs given in some other order. Further-
more, other drugs such as steroids and antiepileptics are administered in conjunction
while treating GBM, which adds another layer of complexity. We believe analyzing
the treatment plans of patients from the TCGA may provide insight to certain drug
sequences, which may be associated with greater overall patient survival. Based on
our knowledge, there is no existing literature that analyzes medication patterns that
may influence survival for new GBM patients.
1.2 Predictive Data Analytics
Predictive analytics is a field used to determine the probable future outcome of an
event or the likelihood of a current state where it is unknown. Data mining in
general helps in characterizing and describing trends and patterns that reside in data
and information but it is limited in terms of preditive models. To encompass the
ability to anticipate occurrence of events in the future predictive analytics comes
into play. It uses a variety of model making tools and algorithms which are used to
characterize and analyze historical information to predict the nature and likelihood
of future events and occurences [34]. The new and useful insights from the data at
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hand helps in making better decisions and verifies the results for continued relevance
and accuracy. [7]
1.2.1 Sequential Mining
Sequential pattern mining refers to the mining of frequently occurring ordered events
or subsequences as patterns [17]. An example of a sequential pattern in the cancer do-
main is ‘patients who are prescribed chemotherapy are likely to get radiation therapy
within 15 days’. Sequential pattern mining has many applications in retail industry
for shelf placement and promotions. Many marketing strategies in big businesses are
formulated based on knowledege gained from sequential mining. This problem first
introduced by Agarwal and Srikant [2] in 1995 based on their study of customer pur-
chase sequences states that “Given a set of sequences, where each sequence consists
of a list of events(or elements) and each event consists of a set of items, and given a
user specified minimum support threshold of min sup, sequential pattern mining finds
all frequent subsequences, that is , the subsequences whose occurrence frequency in
the set of sequences is no less than min sup”. Consider a transaction database S as
shown in Table 1. There are four transactions in the database consisting of items a,
b, c, d, e, f and g. Consider the subsequence s = <a (a c)>. Assuming the min sup to
be 2, we observe that s occurs in three out of the 4 sequences in the database which
is above the threshold support. We call ‘s’ as a significant sequential pattern. This
concept led to the development of the GSP (Generalized Sequence Pattern) mining
algorithm [2] based on the Apriori algorithm to mine frequent itemsets. It uses the
downward-closure property of sequential patterns and adopts a multiple-pass, candi-
date generation approach. Initially individual items that occur more frequently than
a minimum stipulated threshold (known as “support” in these algorithms) are found.
Subsequently it combines frequent items after every iteration and prunes the ones
occurring below the threshold. The process terminates when no more sequences with
3
Table 1: Sequence Database
Transaction ID Sequence of events
1 <a (a c) (a g) g d>
2 <b (a c) a d (e f)>
3 <a (a c) (a d) f e>
4 <(d g) a (a c) f b>
a longer length and meeting the required minimum support can be found. SPADE
(Sequential Pattern Discovery using Equivalent Classes) on the other hand, uses a
vertical data format and associates each itemset with an ID list [48] which is com-
bination of a sequence id and an event id. The former represents the transactions
in a database and the latter indicates the time of occurrence of an event in a given
transaction. The other sequential pattern mining algorithms are based on ‘Frequent
Pattern Growth’ technique [17], avoiding the need for candidate generation unlike
GSP and SPADE which are based on Apriori. PrefixSpan [31] is one such algorithm
which exploits this approach by building prefix patterns and concatenating them with
suffix patterns to find frequent patterns. SPAM (Sequential PAttern Mining using
a bitmap representation) [3] uses a depth-first traversal of the search space and a
vertical bitmap representation of the database enabling efficient support counting.
1.2.2 Supervised Machine Learning: Classification and Prediction
Supervised machine learning is a popular technique used in the area of machine learn-
ing which deals with inferring a function from labelled training data [23]. There are
various algorithms which reason from externally supplied instances and make predic-
tions about the future instances. A concise model is built which is used to assign class
labels to testing instances where the values of the predictor features are known, but
the value of the class label is unknown. The process of applying superivised machine
learning involves identification of required data with respect to the problem at hand
followed by pre-processing the data. We define an unbiased training set which would
be used by a classifier to learn rules to be applied to a test set which is unlabeled.
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Finally the test set is evaluated by one of the validation techniques such as cross-
validation, etc [15].
Classification and prediction are two forms of data analysis to extract models de-
scribing important data classes or to predict future data trends. Regression analysis
is a statistical methodology that is often used for numeric prediction. Data classifi-
cation involves a classifier being developed describing a predetermined set of classes.
In the learning phase the classifier algorithm learns from a training set consisting of
class labels for every database instance. The data set can be numeric data, categorical
data or a mix of both type but the class labels are categorical. Figure 1. depicts the
concept of classification. In the figure a classification algorithm learns and generates
certain classification rules from the training data which are in turn applied to a test
set created from the original data set. Once the classifier has been found to perform
reasonably well, we apply the classifier on new data [17].
1.2.2.1 Logistic Regression
Logistic Regression is a type of probabilistic statistical classification model. It can
be used as a binary predictor, to precict outcome of a categorical dependent variable
based on one or more predictor variables. It measures the relationship between the
categorical dependent variable and one or more independent variables which are con-
tinuous. Logistic regression is usually used in the case where the dependent variable
is binary and is thus called binomial logistic regression. In circumstances where the
number of dependent variables is more than two, it is called multinomial logistic re-
gression. It is analogous to linear regression, except that the dependent variable is
nominal, not a measurement. One goal is to see whether the probability of getting a
particular value of the nominal variable is associated with the measurement variable;
the other goal is to predict the probability of getting a particular value of the nominal
5
Figure 1: Example of classification [17]
variable, given the measurement variable. This method of classification has applica-
tions in many fields including medical and social sciences. It can be used to predict
if a patient has a given disease based on observed characteristics of the patient such
as age, sex, body mass index, lab test results etc. This underlying function of the
this classifier is called the logistic function or the logit function which can take an
input from any value from the negative to positive infinity, but the output would be
always be between 0 and 1 and thus can be interpreted as a probability. The logistic
function is defined as shown in the equation below.
ρ(t) = et/(et + 1) (1)
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Here t is a linear function of a combinatation of explantory variables and expressed
as follows:
t = β0 + β1x (2)
Thus the logistic function can be re-written as
F (x) = 1/[1 + e−(β0 + β1x)] (3)
1.3 Database Evolution
Schema evolution refers to the problem of evolving a database schema to adapt it
to a change in the modeled domain. The problem involves not just studying the
affects of changes in the schema but also how such changes affect the stored data
and existing queries and stored procedures. In the database life cycle, the schema
evolution problem first comes up during the design phase. The evolutive aspect is
more prominent in the post-design phase when a schema may undergo modification
triggered by a significant evolution of the application domain.
Previously managing schema evolution during the operational phase can be prob-
lematic since each schema change needs to take into account previously stored data,
which required storing the previous versions of the schema to retain accessibility to
the associated data [30]. This problem has attracted a lot of attention in the database
community for more than a decade.
It has been observed that a database schema frequently experiences a lot of changes
with time [50]. In most of the domains, there is a lack of a set of common data ele-
ments, that users would like to store in the database thus requiring different database
schemas. In such cases, a static database schema would pose a problem. One ap-
proach to modifying the schema would be to have a database administrator track
the data elements and periodically modify the schema. This would require a lot of
manual labor and periodic updates would eventually delay data entry. In most large
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organizations, the DBA staff has been entrusted with dealing with schema manage-
ment however the costs associated with database management systems and other
large-scale application systems such as EMR (Electronic Medical Record) systems
tend to be prohibitive for most “small-business”, or start-up operations. For most
small outfits dealing with a specialty practice with a handful of physicians, adopting
large generic systems is prohibitive in adoption, training and maintenance costs. The
traditional approach to relational database design starts with the conceptual design
of an application based schema in a model like the Entity-relationship model, then
mapping that to a logical design and eventually representing it as a set of related nor-
malized tables. With time the user requirements change and the database needs to
evolve to meet them. It is also possible that different users in the same organization
using a central database have different requirements. E.g Different clinicians in the
same hospital may want to collect different sets of data elements for patients suffering
for different diseases, with a certain percentage of similarity. In this case we believe
that having data in one place is better than creating different tables with redundant
attributes. We propose a dynamic database modification system (DDSCM) which
can automatically modify the back-end database based on changes made by the user
using a simple user interface.
In chapter 2 we describe an analytics pipeline consisting of different modules to per-
form data standardization, perform sequential mining to extract significant treatment
patterns and predictive analytics to predict patients that are highly likely to survive
for longer than the median survical period of 1 year. The predictive model of the
pipeline uses clinical, genomic and treatment patterns as features and a forward
feature selection algorithm extracts the most predictive features. In chapter 3 we
present a dynamic database schema modification system which automatically evolves
a database at the back-end based on the changes made by the user on the front-end
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with minimal human intervention. This system consists of a templates provided to
the user to feed in data with the capability to modify the templates to accomodate
new data elements. Our approach modifies the back-end database automatically to
reflect the changes in the front-end. In chapter 4 we describe a treatment recommen-
dation tool which combines the analytics pipeline and the dynamic database schema
modification system into a single architecture. The tool also uses the notion of pa-
tient similarity to recommend treatments based on clinically and genomically similar
patients. The tool can be used for a different disease by plugging in the predictive
model of that disease in the analytics pipeline and modifying the database at the




CONSTRAINT BASED TEMPORAL EVENT SEQUENCE
MINING FOR SURVIVAL ANALYSIS OF GLIOBLASTOMA
PATIENTS
One of the many challenges in the field of medicine is to make the best decisions
about optimal treatment plans for patients. Medical practitioners often have differing
opinions about the best treatment among multiple available options. While standard
protocols are in place for the first and second lines of treatment for most diseases, a
lot of variation exists in the treatment plans subsequently chosen. As a representative
disease we study Glioblastoma Multiforme (GBM) which is a rare form of brain tumor.
The goal of our study is to predict patients surviving for greater than the median
survival period for GBM and discover in addition to clinical and genomic factors,
certain treatment patterns which influence longevity. Our study makes the following
contributions:
1. We extend existing sequential pattern mining algorithms by incorporating two
additional constraints called the ‘exact-order’ and ‘overlap’ explained later in
the paper to mine significant treatment patterns from the available data.
2. We follow a data-driven approach to build and evaluate a predictive model
for treatment effectiveness of GBM patients by treating temporal treatment
patterns as features in addition to the existing clinical and genomic features.
2.1 Background
It is important to integrate the clinical data in the EHR with the genomic data of
patients with GBM since they have a poor prognosis and have a median survival of
10
one year.
Sources of Data: TCGA program and cBioPortal
TCGA began as a three-year pilot in 2006 with an investment of $50 million each
from the National Cancer Institute (NCI) and National Human Genome Research In-
stitute (NHGRI). The initiative has a vision that an atlas of changes could be created
for specific cancer types. It also showed that results could be pooled together from
different research and technology teams working on related projects and be made pub-
licly accessible for researchers around the world to validate important discoveries [27].
The cBioPortal [6] is developed and maintained by the Computational Biology Cen-
ter at Memorial Sloan Kettering Cancer Center and provides visualization, analysis
and downloading of large scale cancer genomics data sets. The clinical and treatment
related data about patients was obtained from TCGA and the data pertaining to
mRNA expression, CNV and methylation status of those patients was obtained from
cBioPortal. The mRNA expression levels and CNV data was collected for a specific
set of genes which have been observed to play a role in classifying GBM patients
into 4 genomic subtypes namely classical, mesenchymal, proneural and neural [44].
The methylation status of the promoter region of MGMT gene was also used for our
analysis since it has been observed to have an influence on the survival period of the
GBM patients [14].
2.2 Approach
This section gives an overview of the approach used for representing the data and the
predictive modeling pipeline developed to predict the survival duration of patients.
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2.2.1 Data
We have constructed a rich dataset of newly diagnosed GBM patients by integrating
two different databases called the The Cancer Genome Atlas Portal [27] and the
cBioPortal [6, 11]. TCGA consists of clinical and treatment data pooled together
from different research and technology teams, which is publicly accessible around the
world to validate important discoveries. The genomic data for the same patients was
obtained from cBioPortal, a web resource for multidimensional cancer genomics data
maintained by the Memorial Sloan Kettering Cancer Center.
For our study, we analyzed data from 309 newly diagnosed GBM patients spanning
over a period of 2 years. The data was categorized into ‘Clinical’, ‘Genomic’ and
‘Treatment’ domains. The clinical domain includes demographic information about
the patient along with some basic clinical features such as Karnofsky performance
score (KPS), histopathology, prior glioma history, and whether the patient is alive or
deceased. Under the genomic domain, the mRNA expression levels and CNV data was
collected for a specific set of genes which play a role in classifying GBM patients into
4 genomic subtypes,namely,‘Classical’,‘Mesenchymal’,‘Proneural’, and ‘Neural’ [44].
The methylation status of the promoter region of MGMT gene was also used for our
analysis [14]. The treatment domain consists of treatment plans for each patient. We
use sequential mining algorithms to mine significant patterns in their treatment plans
and use them as features in the dataset in addition to clinical and genomic features.
Table 2 summarizes the dimensions of the dataset categorized by the domain.
The goal of this study is to predict patients who survive for greater than 12 months.
The pool of patients used for the study consists of living patients who have already
survived for more than a year in addition to the deceased patients that constitute the
majority of patients.
12
Table 2: Dataset summary





This section gives an overview of the predictive analytics pipeline developed to predict
long term surviving patients.
2.3.1 Predictive Analytics Pipeline
The pipeline consists of 4 modules, namely, ‘Data Standardization and Cleaning’,
‘Sequential Pattern Mining’, ‘Feature Construction’ and ‘Prediction and Evaluation’.
As shown in figure 2, the raw data is fed into the ‘Data Standardization and Cleaning’
module to filter out noisy data. The ‘Sequential Pattern Mining’ module extracts
significant medication patterns from the treatment data. The clinical and genomic
features are combined with the treatment patterns to form a binary feature matrix
in the ‘Feature Construction’ module, each row corresponding a single patient. It
also assigns a target variable for every patient. The ‘Prediction and Evaluation’
module selects predictive features and performs classification to predict the long term
surviving patients.
2.3.2 Data Standardization and Cleaning
Data standardization is one of the most important and time consuming steps when
building predictive models. Every hospital contributing data to TCGA uses a differ-
ent format to store data and in some cases a different nomenclature for some data
elements. Missing data is another common issue and needs to be imputed if data
is missing for some of the data elements instrumental for our analysis. The data
standardization module identifies these different data formats, missing values, and
13
Figure 2: Predictive Modeling Pipeline
creates a standardized clean data set for further analysis. For instance, 10% data
had missing values for either start or end dates of specific drugs which were imputed
by computing the mean duration of that drug for other patients; Drug names were
‘standardized’- e.g., Temozolomide was changed to Temodar; A value of ‘Completed’
in the additional chemotherapy prescribed column was changed to ‘Yes’.
2.3.3 Sequential Pattern Mining
The data used for this study is modeled as a graph consisting of nodes, categorized
as ‘patient node’ and ‘treatment type node’ and edges categorized as, ‘prescription
edge’ & ‘sequence edge’. A graph offers a much richer picture of a network, and allows
relationships of several types. Since the data model has a path-oriented nature, the
majority of path-based graph database operations are highly aligned with the way in
which the data is laid out hence increasing the efficiency [36]. Figure 3 shows the cur-
rent representation of the data as a graph consisting of two patients just for illustrative
purposes. The patient nodes have properties such as ‘patient id’, ‘age at diagnosis’,
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etc. Prescribed drugs and radiotherapy are represented as treatment type nodes with
properties ‘drug name’ and ‘radiation type’, respectively. The undirected ‘prescrip-
tion edge’ signifies the prescription of treatment with properties corresponding to the
prescription. The ‘sequence edge’ is a directed edge signifying the sequence in which
drugs or radiation were prescribed. E.g., The edge labeled ‘Prescribed’ between the
patient node with ‘id = Patient 1’ and the drug node with ‘drugName = Drug A’
signifies that ‘Patient 1’ was prescribed 200 mg/day of ‘Drug A’ between 05/21/2007
and 06/22/2007. The edge labeled ‘Followed by’ would always be between a radiation
type and a drug, two drugs or two radiation types, signifying the sequence of the pre-
scription. E.g., the ‘Followed by’ edge between source node ‘Drug A’ and target node
‘Drug B’ with properties ‘patient’ and ‘overlap’ signifies that for ‘Patient 1’, Drug B
followed Drug A with an overlap of 24 days. Sequential pattern mining was used to
extract patterns from the treatment data to give three types of information for every
patient: the sequence of drugs/radiation prescribed, their time of prescription within
the sequence and duration of prescription.
A treatment plan for a patient may consist of a combination of multiple drugs or
radiation or both prescribed in a particular sequence. We define a treatment for one
patient as a sequence of events, each event consisting of administration of a treatment
type (drug or radiation). To mine such treatment plans we tailor existing approaches
such as GSP [2] and SPADE [48] by adding two new constraints, namely, ‘exact-order’
and ‘overlap’ constraints (explained in the following sections). We define a concept
of ‘N-path event set’, consisting of a sequence of ‘N+1’ events (treatment instances)
joined by ‘N’ sequence edges. E.g., Drug A ->Drug B ->Radiation D is a 2-path
event set from the graph model shown in figure 3, consisting of two drugs and a radi-
ation therapy forming a sequence of consecutive events (represented as nodes), which
is not a hard restriction in any of the existing algorithms. Since a treatment plan for
a patient may consist of a drug being prescribed more than once, an event identifier
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Figure 3: Data represented as a graph
is added along with each treatment type node to execute the ‘exact-order’ constraint.
2.3.3.1 Exact-Order Constraint
This constraint forces only those events to be a part of sequence, which occur consec-
utively. E.g., if there are multiple drugs (excluding A and B) given between 2 drugs
‘A’ and ‘B’, then a sequence <A B >does not occur.
Candidate Generation : We extract path sequences of length ‘N’ from the data
graph and consider the ones prescribed to a significant number of patients for fur-
ther analysis. This is followed by forming ‘N+1’ path sequences, by increasing the
path-length one edge at a time, and joining on the event ids and the treatment type
nodes. Figure 4 illustrates the candidate generation step, each node representing a
treatment type or a combination of treatment types. Initially a 1-path set consisting
of combinations of two consecutive treatment types is extracted from the treatment
graph such that the sequences should have been prescribed to a significant number
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Figure 4: Illustration of candidate treatment pattern generation
of patients. From these 1-path sets, we form 2-path combinations by joining on the
treatment type node and the event id. The combinations bracketed in green have
the potential to be joined since the resulting sequence has consecutive events. The
ones bracketed in red are not joined since event ‘A’ as the fourth event is different
from event ‘A’ as the second event. This process continues till we cannot form new
combinations or they are insignificant.
2.3.3.2 Overlap Constraint
A ‘treatment plan’ for a patient consists of all the treatment types prescribed to a
patient in a sequence. When a treatment is in effect and another one starts concur-
rently, an overlap of treatment occurs. Two common situations are ‘partial overlap’
and ‘total overlap’ of prescriptions. We say ‘n’ prescriptions (n >1) have a partial
overlap if all the ‘n’ prescriptions are concurrently prescribed to a patient on at least
one day. A total overlap is a special case of partial overlap that occurs when all the
‘n’ prescriptions have the same start and end dates. Approaches called the “Single
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Node” and “Combination Node” approach are formulated. In the ‘Single Node’ ap-
proach a sequence considers each treatment type as a single node as shown in figure
5(a). If there is a partial overlap between two prescribed treatment types, the pre-
scription which ends first becomes the source node and a directed edge connects it
to the other prescription. E.g. A directed edge connects Dexamethasone to Radi-
ation. In case of a total overlap between two prescriptions, both prescriptions are
treated as source nodes, with directed edges to the next treatment type node. E.g
There are directed edges from Temodar and Radiation towards CCNU. The ‘overlap’
constraint, refers to an overlap between multiple drug prescriptions and results in
combining those drugs into a single node and treating it as a single event. Under
the approach called the ‘Combination Node’ approach shown in figure 4(b) a new
node is created whether there is a partial or a total overlap between treatment type
prescriptions. The timeline shown in the figure signifies the order of prescriptions.
The purple colored nodes represent individual drugs and the green nodes are created
to signify overlapping prescriptions. The current approach is based on data about
GBM patients and would be enhanced for other diseases having extensive treatment
guidelines and possibly incorporating potential complications.
2.3.4 Feature Construction
We develop a feature matrix with a feature vector per patient and a target variable
that represents the targeted outcome of treatment. The clinical and the genomic
datasets consist of both numeric and categorical data types. To standardize the data
set and avoid creating a bias, we converted our dataset into a binary feature matrix.
In addition to these features we add to the feature vector each significant sequential
patterns of treatment as a feature. A value of 1 is assigned to this feature for patients
who exactly received that treatment and for others it is set to 0. The target variable
in our study is constructed based on the patient’s survival period. Deceased patients
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Figure 5: Approaches for Treatment Plan Generation. Fig. 5(a) Single Node Approach;
Fig. 5(b) Combination Node Approach
who survived for more than a year are assigned a target variable of ‘1’ and those who
survived for less than a year are assigned ‘0’. For living patients, if their last follow
up date was after one year of diagnosis, they were assigned a target variable of ‘1’
otherwise that patient is discarded since there is no positive conclusion about survival
period.
2.3.5 Prediction and Evaluation
Our goal is to analyze the clinical and genomic characteristics and prescribed treat-
ments within the first year of diagnosis and predict the survival period of patients.
Cross validation is used to partition the data into a training set and a test set multi-
ple times and evaluate the classifier. The sequential treatment patterns are extracted
from the treatment plans of patients in the training set and used as features along
with other clinical and genomic features. A Logistic Regression based classifier is
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trained based on the data at hand. Forward feature selection is used to select predic-
tive features and the prediction performance is evaluated by c-statistic and accuracy.
These features are ranked based on the number of folds in which they were selected
by the greedy algorithm and their p-value.
2.4 Results
2.4.1 Setup
The data used in this study was classified into two classes based on survival period,
namely, i) patients surviving less than a year and ii) patients surviving more than a
year. The survival period for deceased patients can be calculated as the number of
days a patient survived since the day he (from here onwards we would be using ‘he’
to refer to a patients and clinicians without any intended bias) was first diagnosed till
death. From the pool of living patients, the ones who were last seen after one year of
diagnosis were also added to the ‘survival greater than a year’ category. Before the
predictive modeling module, forward feature selection was used to pick only significant
features for the experiment.
2.4.2 Quantitative Analysis
In Table 3, we report the performance of various models using both ‘single node’ and
‘combination node’ approaches with different mixes of features. C-statistic and ac-
curacy from both logistic regression and cox regression methods have been reported.
Amongst the single domain models the best performance is obtained when only the
genomic features are considered. Inclusion of more features increases the predic-
tion accuracy as well as the c-statistic (see table 3). Among the multiple domain
models, the best performance is achieved when features from all three domains are
analyzed together. Table 4 shows the predictive clinical and genomic features along
with influence they have in prolonging overall survival beyond 1 year. The predic-
tive treatment patterns shown in table 5 contain treatment events, which consist of
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the drug/radiation type with the event identifier in curly brackets categorized by the
approach used to form sequences. The bracketed number in the treatment patterns
indicates the order number in the event sequence in which the drugs were prescribed.
Table 3: Performance of various models in predicting patients surviving for >1 year using
Logistic Regression (LR) and Cox Regression (CR).
Single Node Approach Combination Node Approach
Individual Domain Models
C-Statistic Accuracy C-Statistic Accuracy
LR CR LR CR LR CR LR CR
Genomic 0.76 0.75 78.1 % 78.0 % 0.78 0.77 79.5 % 80.1 %
Clinical 0.71 0.71 72.2 % 72.3 % 0.72 0.72 73.4 % 74.0 %
Treatment 0.69 0.70 71.2 % 72.0 % 0.60 0.61 63.3 % 63.1 %
Multiple Domain Models
Clinical + Genomic + Treatment 0.85 0.84 86.4 % 86.7 % 0.85 0.84 86.2 % 87.0 %
Treatment + Genomic 0.84 0.86 84.8 % 84.3 % 0.78 0.78 81.0 % 81.1 %
Clinical + Genomic 0.83 0.83 84.5 % 84.7 % 0.84 0.83 84.5 % 85.2 %
Clinical+ Treatment 0.78 0.79 78.6 % 77.8 % 0.75 0.76 74.5% 74.3 %



















Patient’s age at diagnosis
between 25 & 50 years
40 + 0.018
Karnofsky performance score >70 40 + 0.02
Prescription of Neoadjuvant therapy 30 + 0.002
2.4.3 Qualitative Analysis
In the genomic domain, GBM patients having an unmethylated promoter region of
the MGMT gene are less likely to survive for more than a year. Our results con-
firm prior literature on MGMT methylation status and overall survival. An extensive
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Radiation Therapy{2} ->Treatment Termination 50 - 0.0061
Lomustine{2} ->Treatment Termination 40 - 0.05
Procarbazine{2} ->Treatment Termination 30 + 0.05
Temozolomide{2} ->Lomustine{3} 40 + 0.04
Combination Node Approach
Temozolomide{1}
->[Temozolomide +Radiation]{2} 30 - 0.05
[Temozolomide
+ Radiation]{1} ->Temodar {2}
->Lomustine{3}
30 + 0.04
literature study shows that temozolomide (Temodar), a standard of care chemothera-
peutic, is more effective if the promoter region is methylated [14, 35] leading to better
overall survival with 25% of patient surviving 2 years. A higher expression of TP53
gene is associated with shorter survival periods as opposed to higher expression of the
GABRA1 gene which is associated with longer survival. GABRA 1 gene also called
the gamma-aminobutyric acid (GABA) A receptor, alpha 1. It is characteristic of the
neural subtype of Glioblastoma patients observed to have survived longer than other
genomic subtypes. In the clinical domain, younger patients, in the age group of 25-50
years, have a higher chance of surviving longer.. KPS is a score assigned by clinicians
to GBM patients based on their functional status prior to treatment [28]. Patients
having a score greater than 60 survived longer than a year. Another predictive clinical
factor is neoadjuvant treatment which is given as the first step to shrink the tumor
before the main treatment is begun. Patients receiving neoadjuvant treatment were
found to survive for longer periods. (Neo adjuvant drugs include PolyLCLC, Mivob-
ulin isethionate, Oxaliplatin, O6-Benzylguanine and Carmustine). Most importantly,
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our study also discovered treatment patterns, which have had both positive and neg-
ative effects on the survival period. The standard first line of treatment consists of
surgery followed by fractionated external beam radiation therapy (EBRT) with con-
current and adjuvant temozolomide therapy. This combination is associated with the
best survival in GBM patients and is the standard of care. Fractionated radiation
is given solely for some patients if they cannot tolerate chemotherapy. The single
node approach does not take into consideration overlapping prescriptions, thus using
this approach, we have found that if treatment consists of prescribing EBRT or the
chemotherapeutic CCNU, by itself or along with another drug as the second event
in the treatment timeline, then the likelihood of surviving longer is less. This can
be explained by patients having unresectable tumors. As a result, prescribing EBRT
may not be effective and does not lead to greater overall survival. CCNU prescribed
as the second drug in the treatment is also unusual since most clinicians prescribe the
standard of care temozolomide treatment and CCNU is not prescribed early. Two
treatment patterns were found to have a positive influence on the survival period, one
consisting of Procarbazine prescribed second in the treatment plan in combination
with other drugs or by itself followed by termination of treatment and the second
one consisting of temozolomide prescribed second in the treatment plan immediately
followed by CCNU.
Using the combination node approach, we found that if temozolomide is prescribed
individually as the first event followed by temozolomide with concurrent EBRT then
there is a negative effect on survival. We believe this could be due to the explana-
tion given before about patients not having a resectable tumor or it is also possible
that if radiation therapy is not coupled with Temodar as the first event, which is the
standard of care, then the treatment does not turn out to be effective. The other
predictive treatment pattern, which we have found to have a positive effect on sur-
vival, is temozolomide with concurrent radiation therapy followed by temozolomide
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prescribed individually which is in turn followed by a prescription of CCNU as the
third event.
2.5 Conclusions
In this chapter, we discuss a pipeline performing data standardization, mining se-
quential treatment patterns, and constructing features of predicting GBM patients
surviving for longer periods (greater than 12 months). Sequential mining is applied
to treatments consisting of drugs and radiation, which are termed as events. In the
sequential mining module, we combine GSP and SPADE algorithms and tailor the ap-
proach to account for the exact-order and the overlap constraints. Other than clinical
and genomic features, treatment patterns extracted from the treatment plans of pa-
tients within one year of diagnosis were used as features to predict patients surviving
longer than a year using logistic regression as the classifier and forward feature selec-
tion for selection of predictive features. This study is a preliminary step in providing
extensive treatment guidance to oncologists and neurosurgeons about the efficacy of
certain sequence of drugs and therapies as part of a treatment plan. Currently, the
treatment patterns consist of the drug names and their event of prescription. We are
developing a treatment advisor tool to recommend treatments for a patient based on
treatments given to patients having a similar clinical and genomic profile using the
knowledge of treatment patterns obtained from this study. We also plan to add more
constraints in the model such as a ‘gap’ constraint, which would limit the temporal
gap between events for inclusion in a sequence. We believe this would help in filtering
out clinically insignificant treatment patterns.
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CHAPTER III
DDSCMS: A FORM BASED DYNAMIC DATABASE SCHEMA
CREATION AND MODIFICATION SYSTEM
Nowadays in every domain, the changes in the user requirement are observed very fre-
quently. Also different users in the same organization may have different requirements
and it can be hard to come up with the list of common data elements to be incorpo-
rated in the database. A database administrator is usually responisble to manage the
database schema at the back-end to reflect the changes in the user requirements. We
come up with a form based dynamic database evolution system which automatically
modifies the database at the back-end based on the changes made by the user on the
front-end to minimize the intervention of a database administrator. We propose an
approach to:
1. Create schemas based on predefined forms
2. Update and customize schemas as per changing user needs
3. Align the back-end storage of data as the schemas evolve
Our primary goal is to reduce user intervention and to let the database “evolve”
consistently as time progresses. For developing a generically applicable system, we
base it on the relational model. Our approach to dynamic schema creation and man-
agement has been described here in the context of healthcare just for illustrative
purposes. This project was motivated by our interaction with a local neurosurgery
practice through Dr.Laborde, a neurosurgeon, who convinced us that there is merit
to developing approached to “ad-hoc” database creation and management for appli-
cations where elaborate and costly solutions like EMR and EHR (Electronic Health
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Record) systems are an overkill.
We made some assumptions while developing the prototype. Our current imple-
mentation has been designed to cater to clinical researchers and physicians who want
to use existing data for clinical trials and studies and want to add some parameters
of their own. Very little knowledge about database modeling and query languages is
assumed. The forms could then be made available to the end users such as patients.
The users (physicians, nurses, etc. but not patients) are provided with predefined
forms developed based on the underlying database schema. These forms are auto-
matically generated based on the metadata, which is stored in a separate database.
This process is discussed later in the chapter.
The users can customize these existing forms by adding and deleting data elements
of their choice. As a result of this the tables in underlying database will undergo
appropriate schema modifications as discussed later in the chapter. In our test im-
plementation, we have used a neurosurgery application database from a local clinic
called the ALIF (Anterior Lumbar Inter-body fusion) database [38]. We dealt with
the ALIF data with Dr.Laborde’s expertise as a domain expert in the specific spe-
cialty which deals with surgical procedures of the spine. The term “user” will apply
to physicians , nurses, researchers etc. who are knowledgeable about the application
domain, who can evaluate the suitability of existing forms and who can be guided in
their choices when they undertake to modify the forms. Totally naive end users will
not be a target audience for our approach.
3.1 Technical Challenges and Claims
One of the major challenges we faced while developing this system was to avoid
anomalies or inconsistencies at the back-end when the user makes changes to the
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forms provided for entering the data. The traditional approach to constructing a
relational database application involves building a conceptual schema of the rela-
tional database using a model like the extended entity-relationship model and then
constructing a relational database schema [42]. For most advanced applications the
schema of the relational database changes during development. We are interested
in providing a solution to environments where the database schema needs to be ad-
justed in real time keeping all constraints and rules of a relational database intact
while the user makes changes to the existing forms or creates new forms. This in-
volves maintaining a metadata database to store metadata about the forms (FORMS
DATABASE) and a domain specific database (DSD) to store the actual data entered
by the user. The system also provides an easy to use Form Field Selection feature,
which can be used by novice users to build their own forms.
A dialog based UI is designed to create a new database from scratch or modify an
existing one. It would gather information about the nature of the form field (label
in the form) being added which would in turn lead to appropriate changes in the
schema of the DSD. Addition of a form field leads to formation of a new attribute in
the appropriate table in the DSD. For the data which already exists in the database
before adding a new field, the system populates default values for that particular
field. Deletion of the form field does not lead to deletion of the corresponding at-
tribute from the schema. These deletions are tracked and recorded in a metadatabase,
and a customized form is presented to the user. Modification of a form field does not
modify the field name at the back-end. Mappings are created between the field at
the back-end and the ones in the UI. A new user may choose from any of the existing
customized versions of a form and select the most appropriate one or he (henceforth
we will use the pronoun “he” for the user without any intended bias) may customize
them further based on his requirements. In order to ensure a smooth working of the
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system after plugging in any DSD which stores the data entered via the forms, the
FORMS DATABASE stores the metadata of all forms and also the information about
what tables a form is connected to.
A user is typically shown all available forms, which guide the user to use one that
comes close to their requirements and to modify it. They are also given the option
to create a form from scratch. Our algorithms for storing metadata, for defining the
schema for the back-end, for storing actual data as well as displaying user defined
forms are generic. We propose the mechanism by which a metadata layer called the
FORMS meta-database is created to accommodate the current form definitions and
subsequent changes to it. In this approach, a user can choose to display data elements
that he would like to view together without providing an SQL query. At the back-end
the algorithm performs joins between tables based on primary key-foreign key rela-
tionships and displays data elements requested by the user. The user can also request
the system to perform aggregation operations on data elements, add conditions as
well as sort the results. This is particularly geared for researchers who would want
to do studies or clinical trials using patient treatment data related to a specific drug
as the DSD. They would then create a new database after appropriate aggregation
to define a cohort of patients.
3.2 Approach to Dynamic User Interface Management
The user interface of the system is a form-based UI since its functionality is guided
by a set of forms. The user is provided with two modes; one of them deals with ‘Data
Entry’ and the other with ‘Data Retrieval’. Data entry can be done by either using
the existing template forms provided by default based on the current state of the
DSD, or the existing forms may be customized to suit new requirements before being
used to insert data. The users can also create new forms if the requirements for the
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data they want to enter are not met. These changes are automatically translated into
appropriate modifications at the schema level.
A large set of options is provided to the user as to what type of form field he wants
to create for his form. The options are Radio buttons, Checkboxes, textboxes, drop-
downs and buttons. Any of these options apply while modifying existing forms or
creating new forms. On creating a new form field, the user is required to provide
details about its data type, default value, ability to have multiple values, etc. helping
the system to make appropriate modifications in the database. Similarly, creation of
a new form requires some information from the user which helps in creating a new
table at the back-end. E.g. information regarding its relationship with the existing
forms, cardinality of the relationship, etc. The UI has help buttons to describe the
semantics of these questions in simple language with examples.There may be a class
of users such as researchers that may use an existing large database, create a form
using our tool and then modify the form slightly to add some fields/attributes of their
own using the data entry function.
The other important feature of this system is ‘Data Retrieval’ which is used for
retrieving data by generating queries based on user input. The operations currently
handled by the system are ‘Select’, ‘Aggregation’, ‘Group By’, and ‘Having’. Appro-
priate selections may be made by the user and on doing so the system builds the
query and displays the results after validation. Figure 6 illustrates the process flow
adopted by the system.
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Figure 6: Process flow of the system
3.2.1 Data Entry
The user is presented with template forms based on the underlying DSD. He has a
choice of either using the available forms to enter data or customize the forms appro-
priately. In the latter case he uses the Form Field Panel which displays the potential
types of form fields available. A dialog is initiated with the user, which requires him
to provide details about the form field chosen. For example, if a radio button is
selected for a field ‘Gender’, then he is required to enter the number of options he
wants to keep for this field and their corresponding labels. The new form field added
to a form would become a new attribute in the corresponding table having the rest
of the form fields of that form after the user provides information about this new
attribute using an ‘Add New Form Field’ screen. This information consists of the
label of the form field, it’s data type, e.g Integer, String, etc. The user would also
need to specify a default value of the field which would be stored if the field is left
blank while entering data. This new field may have multiple values e.g If the new
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field which is getting added is ’Symptoms’ then it may contain multiple values since
a patient may have multiple symptoms. This can be specified in the ‘Add New Form
Field’ screen. Each modified template form would be stored as a new version of the
existing template and will be annotated with the username of the user modifying it.
E.g ‘Form A User1’ is ‘Form A’ modified by ‘User1’ and ‘Form A User2’ is ‘Form A’
modified by User2. All the versions of a template are shown to every user from which
he can select one for data entry.
The user may create a new form from scratch for which he would be required
to provide some information about the new type of data he would like to store (See
Figure 7). As mentioned before the ‘?’ marks alongside each label would assist the
user in filling this form. The ‘Form Name’ is the name of the new form the user wants
to create. The ‘Unique Form Field’ would be the field which uniquely identifies an
observation. This is equivalent to the key for that form. Initially this field would
be empty since it is a new form and no fields have been added. The user would
use the ‘Add New Form Field’ screen to add fields to this form. The system allows
selection of multiple fields for the cases when a combination of more than one fields
uniquely identifies an observation. The ‘Related to Form’ field would require the user
to choose from a list of existing forms to which this form is related to. As shown
in the figure ‘Patient’ form has a relationship with ‘Visits’ form in the context of
patients having visits in a hospital. The ‘Cardinality’ can have values 1:1, 1:N and
M:N according to the standard cardinality ratio concept in database modeling [8].
Based on the nature of the relationship between the forms the user needs to select
the cardinality. In the example shown in figure 2, the selected cardinality ‘M:N’
denotes that a single patient may undergo multiple procedures and a procedure may
be done on multiple patients. The label ‘Is there any Attribute for the Relationship’
requires the user to specify attributes which are descriptive of the relationship. E.g.
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Figure 7: New Form Screen
‘No. of Hours’ are the the number of hours that the patient undergoes a particular
procedure. It is neither an attribute of the ‘Patient’ since a patient may undergo
multiple procedures, each for a different amount of time nor of the ‘Procedure’ since
each procedure may be done on different patients, each time for a different number of
hours. It is describing the instance of the relationship ‘undergoes’ between ‘Patient’
and ‘Procedure’. Multiple attributes are allowed via the drop-down menu. Based on
this information the schema of the DSD is modified by adding a new table at the
back-end and relating it to appropriate tables based on the rules discussed in [8, 18].
Appropriate changes are made in the FORMS DATABASE simultaneously. These
rules help creating a new table and relate it to appropriate tables in the database
maintaining consistency.
3.3 Approach to Dynamic Schema Management and Mainte-
nance
Our system has two databases, one is the DSD, which primarily stores the actual data,
that is entered by a user using the forms provided, and the other one is the FORMS
DATABASE that stores the metadata about the forms. The FORMS DATABASE
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is the one primarily responsible for the dynamics of the system and is explained in
more detail in the following section.
3.3.1 Meta-database Schema
This database (see Figure 8) consists of all the information about the form struc-
ture such as the form name, the fields it consists of, the label of each form field,
the type of form fields, etc. needed to build a form. The arrows in the figure stand
for foreign-key to primary-key referential integrity constraints. In our present imple-
mentation the users are provided with already existing form templates pertaining to
the data for a local neurosurgery practice. The database we used for our test was
the already pre-populated ALIF database with information about the template forms.
The table ‘Form’ records a list of all forms provided by the system by default in
a well-annotated format. Any new form created by the user gets added to the list.
The modified form gets stored as a new form and there is a record of which form it
originated from. This table is used to pull out all the forms existing in the current
state of the database for the user to choose from to fill data or to select data elements
to aggregate data as explained before. The table ’Form Field’ stores information
about the different fields present in the form along with the forms that they are a
part of. It also stores the label of the form fields and a detailed explanation of the
field which would translate into a tool tip description in the UI to assist the user in
filling the data. The table ‘Form Field Type’ is created where values such as textbox,
radio-button, check-box, drop-down,etc are stored. The table ‘Form Modifications’
is needed to keep a record of modifications made to the existing form. If a form field
is added or deleted by a user to create his customized form then this table will keep
track of the changes and pull out the customized form fields for users. The ‘Form
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Field Option’ table stores the enumerations of values for the aforementioned types
of form fields. For instance, the form field ‘Gender’ has options ‘Male’ and ‘Female’
which are stored in the ‘Form Field Option’ table.
The table ‘Table Information’ stores the tables, which are present in the actual
database holding the data, which in our case is the ALIF DATABASE. This table
is required for the purpose of aggregating data using the view creation mode where
users have an option of aggregating data elements, which they want to view together.
The table ‘Attribute Information’ stores all the attributes present along with their
data-types and default values in the actual database holding the data. We also keep
track of attributes which are primary keys or foreign keys in a particular table. This
enables the system to decide the table joins when user selects data elements to be ag-
gregated in the view creation mode explained in the following sections. If a user selects
some data elements from a set of tables, which cannot be joined due to the absence
of Primary Key-Foreign Key relationship then the user is prompted against the action
This FORMS DATABASE is populated by acquiring the definition of the un-
derlying DSD, say as an SQL file, with CREATE TABLE statements. The level of
automation is being improved by providing this functionality. The system currently
has the ability to filter out attributes which need not be displayed on the forms.
Our strategy for dealing with schema evolution as the database creation progresses
is explained below. The algorithm can be used to modify an existing database at the
back-end with the help of a dialog based UI or create a new database from scratch.
When modifying an existing database by adding additional forms we already have
the metadata database and the DSD at the back-end contrary to the case when a
new database is created. In the latter case, an unpopulated metadata database exists
at the back-end. As and when the user creates forms at the front-end, the DSD gets
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Figure 8: Schema of the metadata database. The arrows show referential integrity
constraints
developed. We explain our approach for the 2 cases below:
Case 1: Database Schema Modification of the DSD
This is the case when a user chooses to modify existing forms to customize based on
his requirements in turn leading to modification of the DSD schema. The modified
form would be treated as a new form with a new ‘Form ID’. The creation of this new
form is recorded in the ‘Form’ table. In this table the ‘Form ID’ of the original form
is stored, which was modified to create the new form. The modifications would be
stored separately in another table ‘Form Field Modification’ where we store the form
fields that were added or deleted from a particular form to create a new form. Any
form field which gets added to a form first needs to be added to the ‘Form Field’ table,
‘Form Field Type’ table and the ‘Form Field Option’ table appropriately. For every
new form field which gets added to a form, a corresponding attribute gets added to
the existing table which has other attributes corresponding to the other form fields of
the form. This requires population of the ‘Attribute Information’ table with all the
35
information about the new attributes. The ‘data entry’ feature is used to populate
the table with data. If there is data already existing in the table corresponding to
the form being modified then default values of the newly added attributes would be
inserted for these existing observations.
Case 2: Database Schema Creation.
This is the case when a user does not want to use any of the existing templates and
instead creates a new set of forms. This may occur if the data that the user wants to
store pertains to a different domain. He would be required to create new forms from
scratch which would guide the creation of a new domain specific database. At the
metadata level this involves populating the ‘Form’ table with information about the
new forms. The ‘form modified’ field would be ‘NULL’ since we are not modifying
any existing forms to create the new forms. In this case we would also populate
the ‘Table Information’ table with information about the new tables that would be
formed in the new DSD corresponding to the new forms created. Subsequently the
‘Form DSD’ table and the ‘Attribute Information’ table would also be populated as
and when new form fields are added in the forms. The process of creation of new
form fields has been explained in CASE 1.
In both cases, when adding a form field to a form if the form field is supposed
to have atomic values then the corresponding table in the DSD is updated but if the
form field is expected to have multiple values then a new table is created in the DSD
which references the original table corresponding to that form.
3.3.2 Guranteeing consistencies during schema evolution
In our approach a lot of flexibility has been provided to the user in terms of freedom
of choice of creating new forms when the existing form templates do not seem to
be suitable. This can lead to a lot of redundancy at the back-end since a user may
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choose to build a new form instead of modifying existing templates even though his
requirements differ from the existing forms by a small amount. For example, a user
needs only 8 out of 10 form fields of a particular form and wants to add more fields
of his own choice. We would assume that the user would use our feature of modifying
this form by deleting the two irrelevant fields and adding the new extra fields. But
instead it is possible that he creates a new form and adds all the form fields he needs to
this new form. At the back-end this would result in an extra table in the DSD which
would store data being entered via this new form. Periodic reorganization of the DSD
and the metadata database is required. This would involve manually identifying such
redundant tables and integrating them into one table by performing a full outer join
between them. This would be done when the primary keys of the two tables which
are getting integrated are the same. The two keys may have different labels but if
they have the same semantics, we would go ahead with the join. Such merging would
be done only with human approval. If the keys are different then we would keep the
tables as they are. A full outer join may result in a lot of null values in the integrated
tables. Due to the increase in the volume of data and creation of multiple redundant
tables, the decision to go ahead with the integration would depend on the relative
advantage of querying a single table with a lot of null values over querying multiple
tables to get the data.
3.4 Data Retrieval: Query Creation and Validation
The system also supports data retrieval by giving the user a choice of either selecting
existing result sets previously created by users or creating his own. The user is
presented with four types of operations namely ‘Select’, ‘Aggregation’, ‘Group By’
and ‘Having’ to build a query.
1. Select Operation
The user can select fields, which need to be displayed together in the result set.
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This may be done by selecting a table from a drop down list and on doing so
the corresponding attributes of the selected table would be shown.
2. Aggregation Operation
The operation may be used by user to perform aggregate functions like COUNT,
MIN, MAX, AVG, etc on the fields.
3. Group By and Having Operation
If the user decides to use the Aggregation operation then the ‘Group By’ and
‘Having’ operations would be enabled. Using them the aggregated results may
be grouped with respect to certain fields which may or may not be based on
some condition.
The system maintains consistency of the user request as well as of the back-end
operations as follows. If the selected attributes belong to multiple tables then the
system would perform a join between those tables using the Primary Key and Foreign
Key constraints. A ‘Where’ clause is appended to the query being created, to reflect
the join. If there are any attributes that the user has selected to group his result by
then those attributes would be added to the attribute selection list already created
by the ‘Select’ Operation in the first step. If the attributes that the user has selected
require a join of tables, which cannot be joined due to absence of a primary key-
foreign key relationship, then the user would be prompted to change the selection.
If the user has selected some attributes and is also performing aggregation then the
system would remove the selected attributes other than the ones he is grouping by
from the SELECT clause. The user would be prompted of this action. The system
would also check for validity of attributes selected for aggregation. E.g. Calculating
‘Average’ of a non numeric attribute is prevented. After validation the query is
executed and the result is displayed. The user has the choice of saving the result set
with a description of the same. At the back-end the query is stored in the DSD along
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with the description provided and can be executed again when selected by its query
label.
3.5 Related Work
Some research has been done in the area of dynamic schema modification with respect
to a clinical dental relational database [42]. Their approach primarily focuses on han-
dling One-to-Many and Many-to-Many relationships between tables via concepts of
‘detail’ and ‘link’ tables. The user interface developed by the authors is limited to
the dental domain. In our approach the metadata database remains unchanged and
there exists a provision for plugging in any DSD which in turn can be modified by
users. Our application can also be used to create a new database from scratch and
store data while it is created in real time. In addition to this, in [42] the interface
to manage the addition of datasets requires the user to be familiar with the dataset
being loaded after which it is the responsibility of the user to map it to an existing
domain or create a new domain. In our approach the user is oblivious about the
back-end structure. While he creates new form fields or a whole new form, our appli-
cation automatically begins to modify the existing schema by creating new attributes
or relations respectively to accommodate the new data elements. In addition to the
dynamic schema modification approach, a feature of aggregating data and present-
ing the results to the user, which he can store for future use is also supported by
our system. Palisser et al [1] discuss drawbacks of the systems called Orion [16] and
Encore [40]. The former constructs a version of the database state every time any
transformation in the schema takes place. This leads to the problem of managing
multiple versions. The latter focuses on versioning of object types when design en-
vironment object types change in an object oriented database. In our approach on
the other hand the original schema is modified based on the changes requested by
the user but the user is kept unaware of these changes. For instance, a user might
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modify an existing form to create a new customized version but at the back-end the
original schema accommodates the new data elements in an appropriate manner to
avoid resorting to versioning. Kim et al. [19] have handled versioning of object types
as well as schemas for single as well as multi-user design environment in Orion and
also provided semantics of versioning the schema. Ferran et al. [10] discuss an ap-
proach to handle schema and database evolution in O2 object database system. The
algorithm proposed by the authors automatically makes the database consistent on
any update operation performed on the schema. However, depending on what the
updates are, either immediate or deferred transformations are made. Deferred trans-
formations cause problems while implementing complex conversion functions,that the
user needs to specify if the default functions do not suit their needs. Our approach
on the other hand does real time modification of the original schema based on the
changes requested by the user and avoids user intervention to a large extent.
3.6 Use Case
Let us describe the current interface for this prototype used by ALIF practitioners at
a local neurosurgery practice.
1. Basic menu for user [Figure 9]: This figure shows the menu which will be
presented to the user after logging in. It consists of all the template forms
consisting of data elements currently in the back-end database. The last bullet
is “Create New Form” which would be explained ahead. It has a ‘Form Field
Selection’ panel which the user can use when creating new form fields when
needed. The main menu also consists of a ‘Choose Patient’ option which will
help pulling up existing patients in the database when additional data needs to
be entered about them.
2. Ability to use existing forms : On choosing a particular template the corre-
sponding form is displayed for the user to fill in data. This data gets saved in
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the appropriate tables at the back-end.
3. Creating / Updating forms : If the user feels the need to update existing
templates to accommodate data elements, which are not in the form, he can
modify the form using the ‘Add New Form Field’ feature. This creates a new
version of the existing form incorporating the changes requested by the user.
The new form fields added get saved in the back-end database at appropriate
places. The “Create New Form” feature can be selected from the screen shown
in Fig. 4 to create a new form from scratch and add new form fields.
4. View Creation [Figure 10]: The data retrieval feature allows users to select
the fields they wish to integrate together, perform aggregation operations on
them and also group the result set fields of their choice. The result set can be
saved for future use. All screens could not be shown for space reasons.
Figure 9: Basic Menu
3.7 Discussion and Conclusion
3.7.1 Why not NoSQL?
A lot of organizations which collect vast amounts of customer, scientific, sales data
have traditionally stored data in a relational structure, but recently some of these or-
ganizations are tending to use various types of non-relational databases called NoSQL
databases since they have been found to be efficient in handling unstructured data
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Figure 10: View Creation Screen
where there is no fixed schema [?]. In our case we also have a schema that is flexible
since the user can modify it based on his requirement, but we chose not to go for
NoSQL due to the following reasons.
1. Consistency, availability, and partition tolerance are the three properties taken
into consideration when designing a database system. According to the CAP
theorem [?] it is only possible to have two out of these three properties to-
gether in a database system at once. Traditional relational databases maintain
consistency and availability but have trouble with partitions whereas NoSQL
databases are able to maintain either consistency or availability along with par-
tition tolerance. In our case the main goal of the system is providing the user
with all the data in a consistent state and available in user’s expected form.
2. The primary goal of our system is to add flexibility to existing schemas and
dynamically modify them. Since most of the healthcare databases have a rela-




The metadata database in our system plays an important role in driving the dynamic
nature of the DSD which stores tha actual content entered using the forms. The
schema of the metadata database is designed in such a way that the DSD can be
modified without any manual interference. It guides the UI formation and the selec-
tion process of the different UI components other than providing the forms with a
particular structure under different circumstances. The metadata also has the capa-
bility to form queries based on information entered by the users along with verifying
the correctness of those queries.
3.7.3 Conclusion
In this work we proposed a UI and metadata based approach to dynamically modify
and create a database schema which would address the problem of dynamic data en-
try in data-rich environments where the schema can be “built” incrementally as new
data becomes available. It is intended for users with needs for managing data for op-
erational and research purposes but who have no access to DBAs or database design
experts. Template forms are provided to the user but since there may be difference
in requirements between users, the system facilitates modification of existing forms
or create new forms from scratch resulting in appropriate real time modifications in
the database schema keeping the user oblivious to the back-end The changes at the
back-end involve adding new attributes to existing tables, adding new tables, creating
relationships between these new tables and existing tables by assigning appropriate
cardinality, etc. Unlike other systems such as Encore and Orion, our approach does
not create versions of the schema whenever there is a change; instead it creates differ-
ent versions of a single form if needed after modifying the schema appropriately. Our
system also has a data retrieval feature which helps users to aggregate and extract
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data from the database, perform aggregate operations on them and storing the result
sets for future use. This feature does not require the user to write queries instead it
automatically generates and validates queries based on the data elements selected.
There is still a lot of scope for improvement in this system like making the system us-
able for novice users who do not have any knowledge of database modeling concepts.
Given a good domain ontology about synonyms such as WordNet [?] we would like
to automate the process of removing redundant tables. There is a possibility that a
user modifies a form to add a form field, which has semantic equivalence with one of
the existing fields in the form. This would result in redundancy. To avoid such cases
we would like to incorporate semantic validation in the future. The paper represents
preliminary work awaiting field experimentation with small group practices of physi-
cians. It addresses the problems related to relational schema evolution in real-time
which opens up a lot of room for improvement. We have been motivated for the
need of such system in data-rich environments with relatively limited volume such as
medical practices. We are addressing a large user population where the typical user is
not very knowledgeable about database concepts but would like to be able to create
robust databases on the fly. We would like to like to address the aforementioned ideas




The study described in Chapter II forms the basis for developing a treatment recom-
mendation tool for cancer patients. We have developed a prototype for the clinicians
to enter relevant information about a newly diagnosed Glioblastoma patient which
would be fed into the predictive analytics pipeline to predict his time period of sur-
vival. The tool also uses the concept of patient similarity to mine patients that
are clinically and genomically similar to the patient under consideration. The tool
would generate multiple treatment plans for the patient based on how the similar
patients were treated and the significant treatment patterns mined in the study of
GBM patients.
4.1 Related Work
Patient similarity assessment is one of the foundations of every clinical decsion support
system. It involves finding clinically similar patients with the goal of treating them
in a similar fashion. The prime objective is to derive a similarity measure between a
pair of patients based on their EHR data .Sun et. al [41] present a locally supervised
metric learning approach to learn a generalized Mahalanobis distance which is tailored
toward physician feedback. An interactive metric learning method has been developed
which incrementally updates an existing metric based on physician feedback. Defining
a good distance metric in feature space is crucial in assessing patient similarity. Mak
et. al [22] use support vector machines derived from statistical learning theory to
assess patient similarity. A similarity measure is used to generate a similarity score
for different categories features of the disease such as tumor size, degree of liver
damage, etc in the case of liver cancer. The scores quantify the similarity between
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two patients with respect to the corresponding categories. SVM can be used to
combine these similarity measures with statistical learning and then form a model for
classifying the patient pairs into “similar” or “dissimilar” class.
4.2 Architechture and Design
The tool consists of three components: the predictive analytics pipeline, patient simi-
larity and a recommender. Figure 11 shows the arhitecture of the tool. The predictive
analytics pipeline consists of the predivtive model described in chapter II which pre-
dicts whether a patient is likely to survive for longer than a year. A relational database
is used to store the data of for all the patients and their treatment plans in the form
of a graph. The sequential mining sub module which is a part of the pipeline mines
the significant treatment plans and uses them as features in addition to the clinical
and genomic featues to perform the prediction.
Figure 11: Treatment Advisor Tool Architecture
The ‘Patient Similarity’ component is used to find patients from the database who
share a similar profile with the newly diagnosed patient. The similarity assessment
is an important task in healthcare management and in the context of comparative
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effectiveness studies, identifying historical records of patients who are similar to the
new patient could help retrieve similar reference cases to formulate better treatment
plans [41]. The similarity is calculated based on only the predictive features which
were discovered by feature selection algorithm in the predrictive analytics pipeline.
Each feature is assigned a weight by the clinicians based on the relevance of the feature
in measuring similarity between patients. The nature of the data was of a mixed
type consisting of numeric and categorical data types. Some of the categorical data
elements were binary and consisted of 1s and 0s representing presence and absence of
that data element respectively. To remove bias amongst the data elements, we used
the concept of normalization of data. The normalization of a data point was achieved
using the equation below:
x norm = (x max− x)/(x max− x min) (4)
x norm = normalized value of ‘x’
x max = maximum value of ‘x’ in the dataset
x min = minimum value of ‘x’ in the dataset





S = Similarity Score between the newly diagnosed patient and the Nth patient in
the database
m = number of predictive features discovered by the predictive model.
wxi = weight of the i
th feature
Dxi = Distance between the newly diagnosed patient and the N
th patient in the
database.
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The recommender component uses the treatment plans prescribed to the similar pa-
tients found by the patient simiarity component and combines the significant treat-
ment plans found by the pipeline to recommend a personalized treatment plan for
the newly diagnosed patient.
The current implementation of the tool consists of a user interface customized for
Glioblastoma. Fig 12 shows the form which requires clinicians to enter information
about the newly diagnosed patients. Some of the fields include age of the patient,
mRNA expresssion levels of specific genes, the methylation status of the MGMT gene,
etc which were discovered by the forward feature selection algorithm as part of the
predictive model described before. In addition to the information about the patient,
the clinicians can choose to select the number of clinically and genomically similar
patients that need to be analyzed for treatment reference. The range provided by
the tool is from 1 to 10. The data collected by the clinicians is used to calculate the
similarity score with all the patients in the database which have a survival period
longer than a year. The current UI also has the capability to record treatment plans
for patients who already have been undergoing treatment for the tool to recommend
the next best treatment option, but we have not implented this feature yet.
The treatment recommendations are based on the treatments given to the most
similar patients found by the tool and the significant treatment plans which have
been discovered to play an important role in prolonging survival. The screen shown
in Fig 13, shows a ranked list of treatment options for a newly diagnosed patient
based on 3 most similar patients. The clinician can choose any of the treatment plans
from the ranked list for the patient under consideration by clicking on the checkbox
provided. On choosing a plan, the tool compares the chosen plan with the significant
treatment plans extracted by the forward feature selection algorithm to provide any
additional recommendations. The additional suggestions are shown at positions in
the sequence where there is a difference between the events in the chosen plan and
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Figure 12: Patient Record Form
the significant plan. E.g In the example shown in fig 13, the chosen plan consists of
a prescription of Temodar followed by radiation therapy which in turn is followed by
a prescription of CCNU. The additional suggestion section recommends prescribing
a signal transduction inhibitor as the third event instead of the CCNU drug since
prescription of signal transduction inhibitor as the third event in the treatment was
mined as a significant event by the predictive model. The clinician may or may not
choose the suggestions from this section.
4.3 Application of Treatment Advisor Tool
The current implementation of the treatment advisor tool is customized to recom-
mend treatments for Glioblastoma patients. The tool can be easily changed and
customized for another disease using the DDSCMS described in the previous chapter.
One of the important applications of the dynamic schema modification approach is
to incorporate it with the treatment advisor tool to change recommendations in real
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Figure 13: Recommendations
time. We propose an architecture shown in figure 14 consisting of the following:
1. The Treatment advisor tool
2. A database of medical history of patients
3. A database monitoring every patient’s data
4.3.1 Real Time Recommendations
There are many diseases, the treatment for which requires the patient to monitor for
levels of certain proteins and minerals, dietary intake and excercise routines over a pe-
riod of time. One such disease is diabetes mellitus type 2 where self monitoring blood
glucose (SMGB) is an important component of mordern therapy. It is recommended
by healthcare professionals with the goal of achieving a specific level of glycemic con-
trol and prevent hypoglycemia [5]. SMBG is used to collect detailed information
about blood glucose levels by more precise regimens. It is extremely important for
adjustment of a therapeutic regimen in response to blood glucose values and to assist
patients in adjust their dietary intake, physical activity and insulin doeses to improve
glycemic control on a day to day basis.
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We believe that the treatment advisor tool can be used to make real time rec-
ommendations based on data actively recorded by patients. The treatment advisor
tool containing predictive analytics pipeline would directly work on the data stored
in the medical history database and generate an initial set of recommendations for
treating a patient. Based on the recommendations and the severity of the patient’s
condition, the clinician can use the DDSCMS to create a form for the patient and
include the data elements which he requires the patient to monitor. This form can be
customized for another patient if certain data elements are not needed or if additional
ones are required. The data periodically recorded by patients is stored in a relational
database which we call the monitoring database which has a schema corresponding to
the nature of the fields in the form. The treatment advisor tool would be connected
to the monitoring database and would get triggered if the data for one or more data
elements being recorded by the patient fall in the danger levels. In such a case the
the advisor tool would need to make changes in the recommendations accordingly.




Let us describe a use case for this proposed prototype to be used by diabetes special-
ists.
1. First line of recommendation for a newly diagnosed diabetes patient: The
treatment advisor tool would intially find patients clinically and genomically
similar to the newly diagnosed patient and display a ranked list of treatment
options for the clinician to choose from.
2. Form creation for self monitoring: The clinician can use an existing form or
create a new form to add the data elements which need to be recorded by the
patient. The data elements can include blood glucose levels, diet and excercise
information. Appropriate modifications would automatically take place at the
back-end.
3. Triggering the Treatment Recommendation Tool: The data recorded by
the patients using the form provided by the clinician is saved in monitoring
database which is connected to the treatment advisor tool. If at any point of
time the data recorded by the patient falls out of the normal range defined
by the clinician, it would trigger the advisor tool to recommend appropriate
changes in the treatment accordingly.
4. New Recommendations: New recommendations would be requested when data
being recorded for one or more data elements falls out of the normal range set
by clinicians. Once the treatment advisor tool is triggered to make new rec-
ommendations, the clinicians would need to use the DDSCMS to make changes
in the form shown in figure 12 and add these new data elements to find new
clinically similar patients.For example if a patient’s Hemoglobin A1c level drops
below 5, the clinicians would add a field called ‘Latest Hemoglobin A1c Level’
shown in red in figure 15 and get new list of recommended treatments.
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Figure 15: Modified Patient Record Form
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CHAPTER V
CONCLUSION AND FUTURE WORK
In this thesis, we discuss a predictive analytics pipeline performing data standardiza-
tion, mining sequential treatment patterns, and constructing features of predicting
GBM patients surviving for longer periods (greater than 12 months). Sequential min-
ing is applied to treatments consisting of drugs and radiation, which are termed as
events. In the sequential mining module, we combine GSP and SPADE algorithms
and tailor the approach to account for the exact-order and the overlap constraints.
Other than clinical and genomic features, treatment patterns extracted from the treat-
ment plans of patients within one year of diagnosis were used as features to predict
patients surviving longer than a year using logistic regression as the classifier and
forward feature selection for selection of predictive features. This study is a prelimi-
nary step in providing extensive treatment guidance to oncologists and neurosurgeons
about the efficacy of certain sequence of drugs and therapies as part of a treatment
plan. Currently, the treatment patterns consist of the drug names and their event of
prescription. We are developing a treatment advisor tool to recommend treatments
for a patient based on treatments given to patients having a similar clinical and ge-
nomic profile using the knowledge of treatment patterns obtained from this study.
We also plan to add more constraints in the model such as a ‘gap’ constraint, which
would limit the temporal gap between events for inclusion in a sequence. We believe
this would help in filtering out clinically insignificant treatment patterns.
We have also proposed a UI and metadata based approach to dynamically modify
and create a database schema which would address the problem of dynamic data
entry in data-rich environments where the schema can be “built” incrementally as
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new data becomes available. It is intended for users with needs for managing data
for operational and research purposes but who have no access to DBAs or database
design experts. Template forms are provided to the user but since there may be dif-
ference in requirements between users, the system facilitates modification of existing
forms or create new forms from scratch resulting in appropriate real time modifi-
cations in the database schema keeping the user oblivious to the back-end. In the
healthcare domain this tool can be used by the clinicians to create template forms
for the patients to record their diet, exercise schedule and blood sugar in case of dia-
betes. For a different disease the template could be modified or a new one could be
created. The changes at the back-end involve adding new attributes to existing ta-
bles, adding new tables, creating relationships between these new tables and existing
tables by assigning appropriate cardinality, etc. Unlike other systems such as Encore
and Orion, our approach does not create versions of the schema whenever there is a
change; instead it creates different versions of a single form if needed after modifying
the schema appropriately. Our system also has a data retrieval feature which helps
users to aggregate and extract data from the database, perform aggregate operations
on them and storing the result sets for future use. This feature does not require the
user to write queries instead it automatically generates and validates queries based
on the data elements selected.
There is still a lot of scope for improvement in this system like making the sys-
tem usable for novice users who do not have any knowledge of database modeling
concepts. Given a good domain ontology about synonyms such as WordNet [?] we
would like to automate the process of removing redundant tables. There is a possi-
bility that a user modifies a form to add a form field, which has semantic equivalence
with one of the existing fields in the form. This would result in redundancy. To avoid
such cases we would like to incorporate semantic validation in the future. This work
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awaits field experimentation with small group practices of physicians. It addresses the
problems related to relational schema evolution in real-time, which opens up a lot of
room for improvement. We have been motivated for the need of such system in data-
rich environments with relatively limited volume such as medical practices. We are
addressing a large user population where the typical user is not very knowledgeable
about database concepts but would like to be able to create robust databases on the
fly. We would like to like to address the aforementioned ideas of improvement before
making it available to the medical community. We combine the analytics pipeline
model developed for Glioblastoma with the dynamic database schema modification
system to develop an infrastructure for a treatment advisor tool, which in addition to
the aforementioned modules uses a patient similarity module to recommend treatment
options to a newly diagnosed patient by searching for patients with similar attributes.
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